[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"biomarker:c-reactive-protein":3},{"name":4,"total":5,"recruiting":6,"trials":7},"C reactive protein",10,6,[8,16,22,28,34,41,48,55,61,68],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT06570798","A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases",[12],"Phase 2","RECRUITING","2026-08-26T02:15:10.362237Z","2026-07-24T01:27:14.890537Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":20,"content_modified":21},"NCT06130059","Efficacy of LoDoCo in Improving Exercise Capacity Among Patients With HFpEF and Inflammation",[12],"2026-08-26T02:17:58.890423Z","2026-05-05T02:43:29.468583Z",{"nct_id":23,"title":24,"phases":25,"status":13,"updated_at":26,"content_modified":27},"NCT06671054","A Dose Response Study to Evaluate the Efficacy and Safety of Oral AP1189 Administered in Disease-Modifying Anti-Rheumatic Drug (DMARD) naïve Participants Participants With Early Rheumatoid Arthritis",[12],"2026-08-26T02:15:53.461103Z","2026-05-05T02:43:26.741317Z",{"nct_id":29,"title":30,"phases":31,"status":13,"updated_at":32,"content_modified":33},"NCT07656727","A Phase 2 Study to Evaluate the Pharmacodynamics, Safety and Tolerability of BGE-102 in Participants With Obesity and Cardiovascular Risk Factors",[12],"2026-08-26T02:16:18.872924Z","2026-06-18T12:24:03.102151Z",{"nct_id":35,"title":36,"phases":37,"status":13,"updated_at":39,"content_modified":40},"NCT06494501","The Prevent Coronary Artery Disease Trial",[38],"Phase 3","2026-08-26T02:19:22.562392Z","2026-05-05T02:43:27.744105Z",{"nct_id":42,"title":43,"phases":44,"status":13,"updated_at":46,"content_modified":47},"NCT05485961","Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)",[45],"Phase 2\u002FPhase 3","2026-08-26T02:17:00.709807Z","2026-07-19T19:36:05.116191Z",{"nct_id":49,"title":50,"phases":51,"status":52,"updated_at":53,"content_modified":54},"NCT07461961","CORTISHOCK-P: Trial of Corticosteroids in Inflammation-Enriched Heart Failure Cardiogenic Shock",[12],"NOT_YET_RECRUITING","2026-08-26T02:19:19.162260Z","2026-05-05T02:43:28.126871Z",{"nct_id":56,"title":57,"phases":58,"status":52,"updated_at":59,"content_modified":60},"NCT07566325","Assess the Effects of Replacing Foods High in Refined Carbohydrates With Avocado on Biomarkers of Inflammation.",[],"2026-08-26T02:19:25.538428Z","2026-05-13T02:55:06.731069Z",{"nct_id":62,"title":63,"phases":64,"status":65,"updated_at":66,"content_modified":67},"NCT05636176","A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation",[38],"ACTIVE_NOT_RECRUITING","2026-08-03T02:15:56.082035Z","2026-05-05T02:43:27.635900Z",{"nct_id":69,"title":70,"phases":71,"status":65,"updated_at":72,"content_modified":73},"NCT06200207","A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and Inflammation",[38],"2026-08-03T02:56:25.717758Z","2026-05-05T02:35:31.612750Z"]